tiprankstipranks
InnoCare Pharma Ltd. (INCPF)
OTHER OTC:INCPF
US Market
INCPF
InnoCare Pharma Ltd.
RESEARCH TOOLSreports

InnoCare Pharma Ltd. (INCPF) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

INCPF Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
InnoCare
Pharma Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INCPF Stock 12 Month Forecast

Average Price Target

$2.43
▲(56.63% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for InnoCare Pharma Ltd. in the last 3 months. The average price target is $2.43 with a high forecast of $2.73 and a low forecast of $2.17. The average price target represents a 56.63% change from the last price of $1.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.7305116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.427794835,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.169098,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,1.6408085846153846,1.7316171692307694,1.822425753846154,1.9132343384615385,2.004042923076923,2.0948515076923075,2.1856600923076925,2.276468676923077,2.3672772615384616,2.458085846153846,2.5488944307692307,2.6397030153846153,{"y":2.7305116,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,1.6175226796153845,1.6850453592307693,1.7525680388461538,1.8200907184615385,1.887613398076923,1.9551360776923077,2.022658757307692,2.0901814369230767,2.1577041165384614,2.225226796153846,2.292749475769231,2.360272155384615,{"y":2.427794835,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,1.5976229230769232,1.6452458461538462,1.6928687692307693,1.7404916923076923,1.7881146153846155,1.8357375384615384,1.8833604615384616,1.9309833846153845,1.9786063076923077,2.0262292307692307,2.073852153846154,2.121475076923077,{"y":2.169098,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2.73Average Price Target$2.43Lowest Price Target$2.17
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on INCPF
Jack Lin
Morgan Stanley
Morgan Stanley
$2.5→$2.17
Buy
39.94%
Upside
Upgraded
05/28/26
InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan StanleyInnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Shenwan Hongyuan Analyst forecast on INCPF
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
$2.48
Buy
59.70%
Upside
Reiterated
05/13/26
Shenwan Hongyuan Remains a Buy on InnoCare Pharma Ltd. (9969)
CMB International Securities Analyst forecast on INCPF
Jill Wu
CMB International Securities
CMB International Securities
$1.52→$2.34
Buy
50.73%
Upside
Reiterated
04/24/26
InnoCare: Strong Orelabrutinib Uptake and Autoimmune Pipeline Drive Target Price Upgrade and Buy Rating
UBS Analyst forecast on INCPF
Unknown Analyst
UBS
Not Ranked
UBS
$2.53→$2.73
Buy
76.16%
Upside
Reiterated
04/23/26
InnoCare Pharma Ltd. (9969) Receives a Buy from UBS
Guoyuan Securities (HK) Analyst forecast on INCPF
Unknown Analyst
Guoyuan Securities (HK)
Not Ranked
Guoyuan Securities (HK)
$2.14
Buy
38.38%
Upside
Reiterated
12/24/25
SWS Res Analyst forecast on INCPF
Unknown Analyst
SWS Res
Not Ranked
SWS Res
$2.42
Buy
56.41%
Upside
Reiterated
11/17/25
SWS Res Reaffirms Their Buy Rating on InnoCare Pharma Ltd. (9969)
Goldman Sachs Analyst forecast on INCPF
Ziyi Chen
Goldman Sachs
Goldman Sachs
$2.63→$2.92
Buy
88.43%
Upside
Reiterated
10/09/25
InnoCare Pharma Ltd. (9969) Receives a Buy from Goldman Sachs
Guotai Haitong Analyst forecast on INCPF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$3.41
Buy
119.79%
Upside
Reiterated
09/23/25
SPDB Analyst forecast on INCPF
Unknown Analyst
SPDB
Not Ranked
SPDB
$2.68
Buy
72.87%
Upside
Reiterated
08/26/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on INCPF
Jack Lin
Morgan Stanley
Morgan Stanley
$2.5→$2.17
Buy
39.94%
Upside
Upgraded
05/28/26
InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan StanleyInnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Shenwan Hongyuan Analyst forecast on INCPF
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
$2.48
Buy
59.70%
Upside
Reiterated
05/13/26
Shenwan Hongyuan Remains a Buy on InnoCare Pharma Ltd. (9969)
CMB International Securities Analyst forecast on INCPF
Jill Wu
CMB International Securities
CMB International Securities
$1.52→$2.34
Buy
50.73%
Upside
Reiterated
04/24/26
InnoCare: Strong Orelabrutinib Uptake and Autoimmune Pipeline Drive Target Price Upgrade and Buy Rating
UBS Analyst forecast on INCPF
Unknown Analyst
UBS
Not Ranked
UBS
$2.53→$2.73
Buy
76.16%
Upside
Reiterated
04/23/26
InnoCare Pharma Ltd. (9969) Receives a Buy from UBS
Guoyuan Securities (HK) Analyst forecast on INCPF
Unknown Analyst
Guoyuan Securities (HK)
Not Ranked
Guoyuan Securities (HK)
$2.14
Buy
38.38%
Upside
Reiterated
12/24/25
SWS Res Analyst forecast on INCPF
Unknown Analyst
SWS Res
Not Ranked
SWS Res
$2.42
Buy
56.41%
Upside
Reiterated
11/17/25
SWS Res Reaffirms Their Buy Rating on InnoCare Pharma Ltd. (9969)
Goldman Sachs Analyst forecast on INCPF
Ziyi Chen
Goldman Sachs
Goldman Sachs
$2.63→$2.92
Buy
88.43%
Upside
Reiterated
10/09/25
InnoCare Pharma Ltd. (9969) Receives a Buy from Goldman Sachs
Guotai Haitong Analyst forecast on INCPF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$3.41
Buy
119.79%
Upside
Reiterated
09/23/25
SPDB Analyst forecast on INCPF
Unknown Analyst
SPDB
Not Ranked
SPDB
$2.68
Buy
72.87%
Upside
Reiterated
08/26/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering InnoCare Pharma Ltd.

3 Months
Jill WuCMB International Securities
Success Rate
2/4 ratings generated profit
50%
Average Return
+39.40%
Copying Jill Wu's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +39.40% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
2/4 ratings generated profit
50%
Average Return
+20.52%
Copying Jill Wu's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.52% per trade.
2 Years
Jill WuCMB International Securities
Success Rate
3/4 ratings generated profit
75%
Average Return
+53.55%
Copying Jill Wu's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +53.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCPF Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
1
2
3
2
Buy
1
0
1
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
1
3
5
4
In the current month, INCPF has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INCPF average Analyst price target in the past 3 months is 2.43.
Each month's total comprises the sum of three months' worth of ratings.

INCPF Financial Forecast

INCPF Earnings Forecast

Next quarter’s earnings estimate for INCPF is $0.01 with a range of $0.01 to $0.01. The previous quarter’s EPS was <$0.01. INCPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INCPF has Performed in-line its overall industry.
Next quarter’s earnings estimate for INCPF is $0.01 with a range of $0.01 to $0.01. The previous quarter’s EPS was <$0.01. INCPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INCPF has Performed in-line its overall industry.

INCPF Sales Forecast

Next quarter’s sales forecast for INCPF is $179.31M with a range of $179.31M to $179.31M. The previous quarter’s sales results were $76.14M. INCPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INCPF has Performed in-line its overall industry.
Next quarter’s sales forecast for INCPF is $179.31M with a range of $179.31M to $179.31M. The previous quarter’s sales results were $76.14M. INCPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INCPF has Performed in-line its overall industry.

INCPF Stock Forecast FAQ

What is INCPF’s average 12-month price target, according to analysts?
Based on analyst ratings, InnoCare Pharma Ltd.’s 12-month average price target is 2.43.
    What is INCPF’s upside potential, based on the analysts’ average price target?
    InnoCare Pharma Ltd. has 56.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INCPF a Buy, Sell or Hold?
          InnoCare Pharma Ltd. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is InnoCare Pharma Ltd.’s price target?
            The average price target for InnoCare Pharma Ltd. is 2.43. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $2.73 ,the lowest forecast is $2.17. The average price target represents 56.63% Increase from the current price of $1.55.
              What do analysts say about InnoCare Pharma Ltd.?
              InnoCare Pharma Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of INCPF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.